Literature DB >> 1744164

Effects of an androgenic derivative on pre-established mammary tumours chemically induced in the rat.

E Escrich1, T Ribalta, J Muntané, M C Ruiz de Villa, J Murillo, S Saez.   

Abstract

The effects were studied of an androgenic derivative--danazol--administered at doses of 10-12 mg kg-1 day-1 during 97 days to rats with dimethylbenz[a] anthracene-induced mammary tumours. Our main observations were as follows. (a) Danazol did not influence ovarian function at the end of the assay. (b) The treatment with danazol reduced the incidence (P less than 0.05), number of tumours (P less than 0.05) and volume of malignant mammary tumours; on the other hand, the values of these parameters for benign tumours and those of doubtful expression were similar in both experimental groups. (c) Such differential action of Danazol seems to be due to the different incidence and/or content of receptors of both types of tumours. (d) The latter results lead to a hypothesis for the mechanism of action of danazol based on its behaviour at different levels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1744164     DOI: 10.1007/bf01613291

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  29 in total

1.  STEROIDAL HETEROCYCLES. VII. ANDROSTANO(2,3-D)ISOXAZOLES AND RELATED COMPOUNDS.

Authors:  A J MANSON; F W STONNER; H C NEUMANN; R G CHRISTIANSEN; R L CLARKE; J H ACKERMAN; D F PAGE; J W DEAN; D K PHILLIPS; G O POTTS; A ARNOLD; A L BEYLER; R O CLINTON
Journal:  J Med Chem       Date:  1963-01       Impact factor: 7.446

2.  Mammary cancer induced by a single dose of polynuclear hydrocarbons: routes of administration.

Authors:  C HUGGINS; S MORII; L C GRAND
Journal:  Ann Surg       Date:  1961-12       Impact factor: 12.969

3.  Hormonal changes associated with Danazol therapy.

Authors:  G P Wood; C H Wu; G L Flickinger; G Mikhail
Journal:  Obstet Gynecol       Date:  1975-03       Impact factor: 7.661

4.  Treatment of breast cancer with gonadotropin-releasing hormone.

Authors:  A Manni; R Santen; H Harvey; A Lipton; D Max
Journal:  Endocr Rev       Date:  1986-02       Impact factor: 19.871

5.  Standards for the assessment of estrogen receptors in human breast cancer. Report of a workshop on September 29, 1972, at the Antoni van Leeuwenhoek-Huis, Amsterdam.

Authors: 
Journal:  Eur J Cancer       Date:  1973-05       Impact factor: 9.162

6.  Effects of castration of immature rats on serum FSH and LH, and of various steroid treatments after castration.

Authors:  J C Eldridge; W P Dmowski; V B Mahesh
Journal:  Biol Reprod       Date:  1974-05       Impact factor: 4.285

Review 7.  Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs.

Authors:  S S Yen
Journal:  Fertil Steril       Date:  1983-03       Impact factor: 7.329

8.  Evidence that danazol inhibits gonadotropin-induced ovarian steroidogenesis at a point distal to gonadotropin-receptor interaction and adenosine 3',5' cyclic monophosphate formation.

Authors:  M Menon; S Azhar; K M Menon
Journal:  Am J Obstet Gynecol       Date:  1980-02-15       Impact factor: 8.661

9.  Danazol treatment for advanced breast cancer.

Authors:  R C Coombes; D Perez; J C Gazet; H T Ford; T J Powles
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

10.  Estrogenic and antiestrogenic effects of danazol administration in studies of estradiol receptor binding.

Authors:  J R Musich; S J Behrman; K M Menon
Journal:  Am J Obstet Gynecol       Date:  1981-05-01       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.